- Home
- NVCT vs OVID Comparison
NVCT vs OVID Comparison
Compare NVCT & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCT | OVID |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.7M | 562.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NVCT | OVID |
|---|---|---|
| Price | $21.07 | $2.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $10.00 | $4.60 |
| AVG Volume (30 Days) | 168.1K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $5.55 | $1.18 |
| 52 Week High | $29.28 | $3.11 |
Technical Indicators
Market Signals| Indicator | NVCT | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 50.66 |
| Support Level | $17.98 | $2.60 |
| Resistance Level | $23.12 | $2.77 |
| Average True Range (ATR) | 1.47 | 0.10 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 41.23 | 46.81 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.